ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

acoramidis

Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.

Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.

Drug pageAcoramidis: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 6, 202615 company-led studies, 6 open or runningNext primary completion: Sep 17, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BridgeBioits history only114 open or runningphase 4since Jul 6, 2026Sep 18, 2017Apr 15, 2028phase 3 · NCT04988386
AstraZeneca31 open or runningphase 4since Dec 15, 2025Nov 6, 2020Mar 31, 2028phase 4 · NCT07306949
Bayerits history only11 open or runningphase 4since Dec 11, 2025Dec 11, 2025Sep 17, 2027phase 4 · NCT07298044

Also a collaborator on its studies: Celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named acoramidisINNProposed as its International Nonproprietary Name in WHO's List 122
  2. Nov 6, 2020First study: phase 3 study in Symptomatic Transthyretin Amyloid CardiomyopathyFirst studyNCT04622046 · 25 enrolled · Japan
  3. Jul 1, 2021Phase 1 study in HealthyNCT04958135 · 18 enrolled · United States
  4. Dec 15, 2025Phase 4 study in Transthyretin-type Cardiac AmyloidosisNCT07306949 · 200 planned · Japan

Ahead

  1. Mar 31, 2028Primary completion: phase 4 study in Transthyretin-type Cardiac AmyloidosisNCT07306949

TargetBeta

TTR →read by rule
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule

Other programs on TTR

ProgramCompanyFurthest phaseStudies
tafamidisrulePfizerphase 429
coramitugNovo Nordiskphase 33
coramitugNovo Nordiskphase 12

Studies

All 3 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07306949Transthyretin-type Cardiac Amyloidosis · Japan4RecruitingMar 31, 2028200
NCT04958135Healthy · United States1CompletedAug 4, 202118
NCT04622046Symptomatic Transthyretin Amyloid Cardiomyopathy · Japan3CompletedNov 8, 202325

How it is read

Names in the registry

  • “Acoramidis”, 6 entries
  • “Acoramidis (AG10)”, 2 entries
  • “AG10”, 2 entries
  • “acoramidis”, 2 entries
  • “Acoramidis (AG10) oral tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.